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Abstract 
Background: Large contiguous gene deletions at the distal end of the 
short arm of chromosome 9 result in the complex multi-organ 
condition chromosome 9p deletion syndrome.  A range of clinical 
features can result from these deletions with the most common being 
facial dysmorphisms and neurological impairment. Congenital 
hyperinsulinism is a rarely reported feature of the syndrome with the 
genetic mechanism for the dysregulated insulin secretion being 
unknown.  
Methods: We studied the clinical and genetic characteristics of 12 
individuals with chromosome 9p deletions who had a history of 
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neonatal hypoglycaemia. Using off-target reads generated from 
targeted next-generation sequencing of the genes known to cause 
hyperinsulinaemic hypoglycaemia (n=9), or microarray analysis (n=3), 
we mapped the minimal shared deleted region on chromosome 9 in 
this cohort. Targeted sequencing was performed in three patients to 
search for a recessive mutation unmasked by the deletion. 
Results: In 10/12 patients with hypoglycaemia, hyperinsulinism was 
confirmed biochemically. A range of extra-pancreatic features were 
also reported in these patients consistent with the diagnosis of the 
Chromosome 9p deletion syndrome. The minimal deleted region was 
mapped to 7.2 Mb, encompassing 38 protein-coding genes. In silico 
analysis of these genes highlighted SMARCA2 and RFX3 as potential 
candidates for the hypoglycaemia. Targeted sequencing performed 
on three of the patients did not identify a second disease-causing 
variant within the minimal deleted region. 
Conclusions: This study identifies 9p deletions as an important cause 
of hyperinsulinaemic hypoglycaemia and increases the number of 
cases reported with 9p deletions and hypoglycaemia to 15 making this 
a more common feature of the syndrome than previously appreciated. 
 Whilst the precise genetic mechanism of the dysregulated insulin 
secretion could not be determined in these patients, mapping the 
deletion breakpoints highlighted potential candidate genes for 
hypoglycaemia within the deleted region.
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            Amendments from Version 1
Following the requests of reviewers, the title of the manuscript has 
been changed to highlight that 9p deletions cause Congenital 
Hyperinsulinism. The description of the clinical characteristics 
of the cohort have been updated to confirm that hypopituitarism 
was excluded as a cause of hypoglycemia in these patients. The 
results section has been updated to clarify which patients had 
been screened for mutations in the known hyperinsulinism genes. 
The manuscript now includes discussion on the disruption of 
imprinted genes by large deletions. Figure 1 has been updated to 
include patient 3, the ID for the patient listed on Decipher and the 
size of the minimal deleted region. The SDS birthweights for the 
cohort have been added to Table 1 and the age at remission for 
patient 3 has been included. Table 2 has been expanded to show 
whether disruption of genes residing within the minimal deleted 
region are known to cause human disease.
Any further responses from the reviewers can be found at the 
end of the article
REVISED
Introduction
Monosomy of part of the short arm of chromosome 9 causes 
the complex congenital condition chromosome 9p deletion 
syndrome (MIM: 158170)1. These large contiguous gene dele-
tions can occur in isolation or form part of an unbalanced 
translocation2. The cardinal clinical features of the 9p dele-
tion syndrome are craniofacial dysmorphisms, including trigo-
nocephaly, midface hypoplasia, flat nasal ridge, long philtrum, 
short neck and developmental delay. Other common features 
include musculo-skeletal abnormalities, congenital heart defects, 
abdominal wall defects and disorders of sexual differentiation3. 
A further rare feature is hypoglycaemia, which has been 
described in 3 of the >100 genetically confirmed cases4–6.
The phenotypic heterogeneity observed between individu-
als with the chromosome 9p deletion syndrome is likely to 
reflect differences in the extent of the deletion, with individual 
features resulting from haploinsufficiency of a specific gene(s). 
An example is seen in males with 46,XY gonadal dysgenesis 
(MIM: 154230) which has been linked to disruption of the 
putative sex-determining genes DMRT1 and DMRT2 on 9p7.
Recent efforts have focussed on defining the critical region 
for the 9p deletion syndrome but there have been some differ-
ences in results. Swinkels et al. refined the critical region to a 
300 kb stretch of DNA on 9p22.3; however, this region did not 
overlap with the critical region mapped by Faas et al.3,8. 
Given the differences in the craniofacial features between the 
cohorts reported it seems likely that there is not a single 
‘critical region’ for the 9p deletion syndrome but rather that 
the syndrome represents a phenotypically and genetically 
heterogeneous group of disorders with the extent of the dele-
tion, and in some cases the reciprocal trisomy, determining 
the phenotype.
Congenital hyperinsulinism is a rare condition of hypogly-
caemia due to dysregulated insulin production from pancre-
atic beta cells9. Despite major advances in genetics the under-
lying cause of congenital hyperinsulinism is not identified 
in approximately 55% of patients10. Studying patients with 
congenital hyperinsulinism and the 9p deletion syndrome provides 
an opportunity to further unravel the genetic underpinnings of 
dysregulated insulin secretion in congenital hyperinsulinism.
In this study we investigated the clinical and genetic charac-
teristics of 12 patients with congenital hypoglycaemia and a 
large deletion on chromosome 9p. We mapped the genomic 
breakpoints in all 12 patients which allowed for refine-
ment of the critical region for hypoglycaemia to 7.2 Mb 
encompassing 38 genes. We sought to identify candidate genes 
for congenital hyperinsulinism in this region, an approach 
which has been successfully employed for gene discovery in 
other conditions11.
Methods
Cohort
A total of 12 patients with large deletions of the short arm of 
chromosome 9 were identified (as described below) following 
referral for genetic testing for congenital hyperinsulinism or 
a history of neonatal hypoglycaemia. Informed consent for 
publication of the patients’ details was obtained. This study 
was approved by the North Wales Research Ethics Committee 
(517/WA/0327).
The DECIPHER database was searched for individuals who 
had hypoglycaemia and deletions of chromosome 9p which 
overlapped with the deletions identified in our cohort6.
Calling deletions
In nine patients multiple syndromic features had prompted 
microarray analysis leading to the identification of a 9p 
deletion. In the remaining three patients a deletion on 9p was 
detected using SavvyCNV (release 1) using off-target reads 
from the next-generation sequencing analysis of the known 
congenital hyperinsulinism genes. This technique calls 97.5% 
of true CNVs >1Mb12.
Break points were mapped in patients 1-9 using off-target 
reads from the targeted next generation sequencing data. In 
these patients analysis of the known hyperinsulinism genes did 
not identify a mutation. In patients 10-12 the breakpoints were 
mapped by microarray analysis, DNA was not available for 
targeted sequencing in these individuals.  In 5/11 patients the 9p 
deletion formed part of an unbalanced translocation (Table 1).
Sequencing of the deleted region
To search for recessive mutations unmasked by the deletion, 
next generation sequencing was performed in three patients 
following targeted capture of the Chr9p24 region (patients 4, 
5 and 6, Table 1). Illumina-compatible libraries were prepared 
after fragmentation of genomic DNA to ~200bp average size, 
then enriched for target regions using a custom RNA bait library 
designed against chr9:1-7,834,443 (GRCh37/hg19) with 
medium stringency against repetitive sequences (Prognosys 
Biosciences Inc., formerly of La Jolla, CA). Hybridization, 
capture, washing and amplification (15 cycles) were performed 
using a Rivia Targeted Enrichment Kit according to the 
manufacturer’s instructions (Rivia, formerly of La Jolla, CA). 
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Libraries were sequenced on an Illumina HiSeq 2000 using 
100 base paired-end reads.
Sequence data was analysed using an approach based on the 
GATK best practice guidelines13. Reads were aligned to the 
GRCh37/hg19 human reference genome with BWA mem 
(version 0.7.15)14 followed by local re-alignment using GATK 
IndelRealigner (version 3.7.0)15. Large sections of the region 
are low complexity and while mean target coverage was 
36X, 34X and 41X, only 56%, 56% and 58% of the minimal 
deleted region was covered at 10X or above in the three sam-
ples, respectively. Variants were called using GATK haplo-
type caller and annotated using Alamut Batch (Interactive 
Biosoftware version 1.11, Rouen, France) (an open-access 
equivalent is ANNOVAR).16. We excluded variants present 
in gnomAD17 at a frequency greater than 1 in 27,000 - the 
highest published prevalence of hyperinsulinism in an outbred 
population18. Variants that were homozygous in internal controls 
(n = 65) and intronic variants that were not predicted 
to affect splicing by the in silico tools MaxEntScan19, 
SpliceSiteFinder-like20, and NNSPLICE21 were excluded.
Evaluation of protein expression of candidate genes in 
deleted region
The expression of genes within the deleted region was 
assessed by the median transcripts per million value from the 
Genotype-Tissue Expression (GTEx) portal.
Results
Clinical characteristics
Clinical characteristics of the cohort are provided in Table 1. 
Hypoglycaemia (blood glucose <3.0 mmol/l) was diagnosed 
in 9/12 patients at birth and in three patients at the age of 
3 days, 8 weeks and 20 weeks respectively. In all patients 
cortisol deficiency was excluded clinically and biochemically at 
diagnosis and no patients had evidence of growth failure. In 
10/12 patient’s in our cohort and one patient reported in the 
literature4 detectable insulin at the time of hypoglycaemia 
confirmed a diagnosis of congenital hyperinsulinism which 
was treated with diazoxide. In the four remaining patients, two 
from our cohort (patients 3 and 12) and two from the 
literature, a diagnosis of congenital hyperinsulinism was not 
confirmed. In three of these patients insulin was either not 
measured or the results were not reported (patient 12, 
reference 5 and https://decipher.sanger.ac.uk/patient/249708). In 
the final patient (patient 3) insulin was measured at the time of 
hypoglycaemia but was suppressed (less than 6.0 pmol/L). 
The duration of hypoglycaemia varied considerably within our 
cohort with one child having transitory hypoglycaemia not 
requiring treatment yet another patient requiring ongoing 
diazoxide treatment at 8 years.
Two patients within the cohort (patients 10 and 11) were 
affected siblings; the remaining 10 patients were unrelated 
and had no family history of hypoglycaemia. Extra-pancreatic 
features previously reported in patients with Chromosome 
9p deletions were observed in all individuals although there was 
no uniform phenotype. Common features reported in our cohort 
include cardiac anatomical defects in seven patients, facial 
dysmorphism in ten patients, digit/limb abnormalities in six 
patients and undervirilisation in four patients (Table 1).
The minimal deleted region for hypoglycaemia is 7.2 Mb
Analysis of sequence data confirmed deletions on chromosome 
9p which ranged in size from 7.2 Mb to 19.2 Mb. These 
were aligned and compared to the deletions identified in 
the two patients reported in the literature and an individual 
listed on the DECIPHER database with a 9p deletion and 
hypoglycaemia4,5 (https://decipher.sanger.ac.uk/patient/249708). 
The minimal deleted region shared between the 15 patients 
spanned 7.2Mb (Chr9:0-7200000[hg19], 9p24.3-9p24.1) 
(Figure 1). 
Figure 1. Diagram showing the deletions in our patients (patients 10 and 11 are siblings) and three other reported patients with 9p 
deletions and hypoglycaemia. Details of the size of the individual deletions are provided in Table 1. A list of the NCBI RefSeq genes within 
the 7.2Mb minimal deleted region is provided in Table 2.
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Table 2. Data on the genes within the minimal deleted region 
(Chr9:0-7200000[hg19], 9p24.3-9p24.1). pLI scores were obtained 
from gnomAD. Pancreatic expression was obtained from the 
Genotype-Tissue Expression (GTEx) portal (gtexportal.org). NA 
indicates the gene was not found in this database. When disease-
causing mutations have been reported details of the associated 
syndrome and the inheritance of mutations are provided.
NCBI 
RefSeq 
Gene
gnomAD 
pLI
Pancreatic 
expression 
GTEx 
(median 
transcripts 
per million)
Disease-causing gene 
OMIM ID (Phenotype, 
Inheritance)
WASHC1 NA NA -
FOXD4 0 0.27 -
CBWD1 0 1.705 -
DOCK8 0 1.79 # 243700 (Hyper-IgE 
recurrent infection 
syndrome. Recessive)
KANK1 0 8.72 # 612900 (Cerebral palsy, 
spastic quadriplegic, 2)
DMRT1 0.74 NA -
DMRT3 0 0 -
DMRT2 0.01 0.02 -
SMARCA2 1 13.4 # 601358 (Nicolaides-
Baraitser syndrome. 
Dominant)
VLDLR 0 8.84 * 192977 (Cerebellar 
hypoplasia and mental 
retardation with or without 
quadrupedal locomotion 
1. Dominant)
KCNV2 0 0.07 * 607604 (Retinal cone 
dystrophy 3B. Dominant)
PUM3 NA NA
RFX3 1 1.18
GLIS3 0 3.52 # 610199 (Diabetes 
mellitus, neonatal, 
with congenital 
hypothyroidism, 
Recessive)
SLC1A1 0 1.47 # 222730 (Dicarboxylic 
aminoaciduria, 
Recessive)
SPATA6L 0 2.04 -
CDC37L1 0.97 6.83 -
PLPP6 NA NA -
AK3 0 24.6 -
RCL1 0.06 6.52 -
The minimal deleted region for hypoglycaemia includes 38 
genes
The 7.2Mb minimal deleted region on Chromosome 9 con-
tains 38 protein-coding NCBI RefSeq genes (Table 2). Of these, 
SMARCA2, RFX3, CDC37L1 and UHRF2 have a gnomAD 
pLI score of >0.9 indicating that they are intolerant to loss-of-
function variants17. The three genes with the highest levels of 
NCBI 
RefSeq 
Gene
gnomAD 
pLI
Pancreatic 
expression 
GTEx 
(median 
transcripts 
per million)
Disease-causing gene 
OMIM ID (Phenotype, 
Inheritance)
JAK2 0.65 2.43 # 600880 (Budd-Chiari 
syndrome, Somatic)
INSL6 0 0 -
INSL4 0 NA -
RLN2 0 0.151 -
RLN1 0.01 0.0404 -
PLGRKT 0 5.03 -
CD274 0.2 1.2 -
PDCD1LG2 0 0.167 -
RIC1 NA NA # 618761 (Catifa 
Syndrome, Recessive)
ERMP1 0 4.7 -
MLANA 0 0.0957 -
KIAA2026 0.66 4.04 -
RANBP6 0 5.44 -
IL33 0 1.57 -
TPD52L3 0.2 0 -
UHRF2 1 6.91 -
GLDC 0 0.0397 # 605899 (Glycine 
encephalopathy, 
Recessive)
KDM4C 0 5.15 -
expression in the pancreas are AK3, SMARCA2 and VLDLR 
all with a median transcripts per million value of >8 on the 
Genotype-Tissue Expression (GTEx) portal. Three further 
genes (KANK1, RFX3 and JAK2) are involved in pathways 
associated with insulin regulation according to the UniProt 
gene ontology database22.
To test whether the deletion was unmasking a second reces-
sively inherited mutation on the opposite allele we performed 
targeted capture followed by next generation sequencing of the 
minimal deleted region in three unrelated individuals. No rare 
variants shared by all three samples were identified. We also 
searched for genes harbouring different rare variants in each 
of the three samples but did not identify any genes which met 
this criterion.
Discussion
Our cohort of 12 patients with 9p deletions and hypoglycaemia 
is the largest reported series and significantly widens the phe-
notypic spectrum over and above the three reported cases. 
In 10 of the 12 patients congenital hyperinsulinism was con-
firmed, whilst in two patients insulin was either not measured 
at the time of hypoglycaemia or was shown to be appropriately 
suppressed. Variability in extra-pancreatic phenotypes was 
observed in our cohort with specific features likely to be 
determined by the extent of the deletion in each patient and 
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in five cases the reciprocal trisomy. This study allowed the 
refinement of the critical region for the Chromosome 9p deletion 
syndrome which features hypoglycaemia to 7.2 Mb. The 
critical gene(s)/regulatory region(s) within this locus are not 
known.
As insulin was appropriately suppressed in one patient in our 
cohort and was not measured in three further individuals we 
cannot be certain that hypoglycaemia results from dysregu-
lated insulin secretion in all cases with a 9p deletion. If these 
four patients do have a different mechanism for hypoglycae-
mia compared to the congenital hyperinsulinism group, we 
would, however, not expect the size of the minimal deleted 
region for congenital hyperinsulinism calculated in this report 
to change given that the deletions in these patients were not 
critical for determining the boundaries on the 7.2 Mb region 
(Table 1 and Figure 1).
There are four possible mechanisms by which large deletions 
can cause disease: 1) disruption of a gene at the breakpoint 
2) haploinsufficiency of a gene within the deletion 3) unmasking 
a recessive mutation in a gene within the deleted region and 
4) disruption of an imprinted gene. None of the genes 
within the deleted region are known to be imprinted and the 
breakpoints for the deletions varied between patients in our 
cohort, making it unlikely that the disruption of a gene at 
a breakpoint is the cause of the hypoglycaemia in these patients. 
We performed targeted sequencing of the minimal deleted 
region to search for recessive mutations but did not iden-
tify any variants which could explain the phenotype. Although 
it is possible that our approach may have missed a muta-
tion, given that only 56% of the minimal deleted region was 
captured at ≥10X coverage in three patients, from our data the 
most likely explanation it that haploinsufficiency of one or more 
genes within the minimal deleted region is responsible for the 
hypoglycaemia. If this is true we would expect this aetiology 
to be associated with variable penetrance given that patients 
without hypoglycaemia and deletions over this region have 
been reported3. This variable penetrance would be similar to 
what is observed with the gonadal dysgenesis phenotype 
where 46,XY patients with 9p24 deletions and normal male 
external genitalia have been reported3,7.
Interestingly, the deletions in four patients within our cohort 
do not overlap with the 3.5 Mb minimal deleted region defined 
by Faas et al.8 and only two of our patients had a deletion 
which overlapped with the 300 kb critical region identified by 
Swinkels et al.3. The majority of deletions in our patients 
were called from sequence data by savvyCNV8 which maps 
breakpoints with an estimated accuracy of ±200 kb. Even 
including this margin of error, not all of our patients have 
deletions which overlap with either of the previously identified 
critical regions. This is in keeping with the 9p deletion 
syndrome being a genetically and phenotypically heterogeneous 
collection of overlapping syndromes.
In conclusion, our study identifies 9p deletions as an impor-
tant cause of hypoglycaemia and refines the critical region 
for this phenotype to 7.2 Mb. Whilst we highlight potential 
candidate genes the genetic mechanism for the hypoglycaemia 
in our patients remains unknown. Further studies are required to 
investigate the cause of hyperinsulinism in these patients and 
in those with other copy number variant (CNV) syndromes 
which feature congenital hyperinsulinism such as Turner’s 
syndrome where the causative gene(s) have also not been 
definitively identified23,24. These large deletions can be screened 
for by targeted panels using an off-target CNV caller such as 
SavvyCNV12.
Data availability
Underlying data
The genotype data could be used to identify individuals and 
so cannot be made openly available. Access to data is open 
only through collaboration. Requests for collaboration will 
be considered following an application to the Genetic Beta 
Cell Research Bank (https://www.diabetesgenes.org/current-
research/genetic-beta-cell-research-bank/). Contact by email 
should be directed to the Lead Nurse, Dr Bridget Knight 
(b.a.knight@exeter.ac.uk).
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The study was well designed and the manuscript was well structured and written. I 
will recommend to index the MS after comments below are addressed. 
 
1.    Figure 1 illustration of deletion seems not consistent with the deletion data shown 
in table 1. Either one should have error.  
 
We thank the reviewer for their appraisal of our manuscript. We are grateful for 
highlighting the discrepancies between table 1 and figure 1. A new version of figure 1 has 
now been uploaded which includes patient 3 (omitted by mistake in the previous version). 
The tables and figure have now bee double checked. 
 
2.    Did author test those genes associated with hypoglycemia to rule out pathogenic 
variants on those genes for these cases? 
 
We apologise that this was unclear. We had excluded all known causes of congenital 
hyperinsulinism in 9 of the 12 patients. In the three remaining patients samples were 
unavailable to targeted next-generation sequencing. We have updated the methods to 
reflect this point. 
 
3.    The NGS data for the sequencing didn't achieve enough depth and coverage to 
rule out the third possible mechanism mentioned by author: unmasking a recessive 
mutation. I understand authors already discussed a little bit about his, but a more 
comprehensive analysis of NGS data with enough depth and coverage will strength 
the conclusion of this paper. However, I wouldn't say this is necessary to index. 
 
We agree with the reviewer that it has not been possible to rule out a missed recessive 
mutation given the depth/coverage of the sequencing, which we hope is reflected in the 
text of our discussion.   
Competing Interests: None
Reviewer Report 18 June 2020
https://doi.org/10.21956/wellcomeopenres.16912.r38980
© 2020 Brunetti-Pierri N. This is an open access peer review report distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Nicola Brunetti-Pierri   
Telethon Institute of Genetics and Medicine, Naples, Italy 
Banjerjee and colleagues report 12 patients with 9p deletions and hypoglycemia. They also 
defined the minimally deleted interval trying to pinpoint the gene responsible for the metabolic 
defect. 
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The paper is well written and provides novel information. However, there are several issues that 
require attention: 
There are discrepancies between Fig. 1 and Table 1:a) Patient 3 is reported to have a 17.6 
Mb deletion on table 1 (larger than the deletion of patient 2) but according to figure 1, the 
deletion is smaller than patient 2.b) Deletion size is similar between patients 6-7-8-9 and yet 
patient 9 is shown in fig-1 to have a larger deletion. Patient 4 and 5 deletions should be 
similar in size according to the table. 
 
1. 
In Fig. 1: patient 12 is not shown. Why there is a single base for 9/10? 
 
2. 
Table 1: why there is a ‘not applicable’ for the age of hypoglycemia remission of patient 3? Is 
it not available? 
 
3. 
Indicate on the table that the glucose levels were at the time of onset of the hypoglycemia. 
 
4. 
Please add whether each patient was AGA, SGA or LGA according to their birth weight and 
gestational age. 
 
5. 
Dose of diazoxide is not included in all cases. 
 
6. 
Please change age at diagnosis to ‘onset’ to make clear it refers to the hypoglycemia. 
 
7. 
Fig. 1 should include the size of the deletions and an Ensembl/USC snapshot of the genes 
included in the minimally deleted interval. 
 
8. 
Is any of the genes in the interval imprinted? Imprinting would be a fourth mechanism that 
the authors can include in the discussion. Moreover, there are defects of imprinted genes 
known to cause hyperinsulinism (e.g., 11p15 region) and neonatal diabetes. 
 
9. 
Discuss whether haploinsufficiency for the genes in the interval are responsible for any 
known syndromes and whether these syndromes have been associated to hypoglycemia. 
 
10. 
Can the authors estimate the frequency of the hypoglycemia among all reported cases of 9p 
deletions? This estimate would help understanding whether mutations on the undeleted 
allele might be implicated. Given the apparently higher frequency of hypoglycemia in 9p 
deletion cases, one would predict that the underlying mechanism for hypoglycemia it 
cannot be due to unmasking of a recessive allele. 
 
11. 
Add DECIPHER ID for the case included on fig. 1.12. 
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
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Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Medical Genetics
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 24 Jul 2020
Sarah Flanagan, University of Exeter Medical School, Exeter, UK 
Banerjee and colleagues report 12 patients with 9p deletions and hypoglycemia. They 
also defined the minimally deleted interval trying to pinpoint the gene responsible for 
the metabolic defect. The paper is well written and provides novel information. 
However, there are several issues that require attention 
 
1.    There are discrepancies between Fig. 1 and Table 1:a) Patient 3 is reported to have 
a 17.6 Mb deletion on table 1 (larger than the deletion of patient 2) but according to 
figure 1, the deletion is smaller than patient 2.b) Deletion size is similar between 
patients 6-7-8-9 and yet patient 9 is shown in fig-1 to have a larger deletion. Patient 4 
and 5 deletions should be similar in size according to the table. Fig. 1: patient 12 is not 
shown. Why there is a single base for 9/10? 
 
We thank the reviewer for their thorough review of our manuscript and for highlighting the 
discrepancies between the table and the figure. We had mistakenly uploaded a previous 
version of figure 1 for peer review which had not included patient 3, this patient had been 
included in the table. A new figure has been uploaded and the data double checked. 
   
2.    Table 1: why there is a ‘not applicable’ for the age of hypoglycemia remission of 
patient 3? Is it not available? 
 
The table has been updated to show that the child had normal glycaemia at the age of 7 
months. 
   
3.    Indicate on the table that the glucose levels were at the time of onset of the 
hypoglycemia. 
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The table has been updated as requested. 
   
5.    Please add whether each patient was AGA, SGA or LGA according to their birth 
weight and gestational age. 
 
The birth weight standard deviation score for each patient has been added to table 1. We 
would prefer to add SDS scores than AGA/SGA/LDA.  
   
6.    Dose of diazoxide is not included in all cases. 
 
We had included all of the information that we have available to us regarding diazoxide 
dose. When the dose is unavailable we had noted this in the manuscript.  
   
7.    Please change age at diagnosis to ‘onset’ to make clear it refers to the 
hypoglycemia. 
 
The table has been updated as requested. 
   
8.    Fig. 1 should include the size of the deletions and an Ensembl/USC snapshot of the 
genes included in the minimally deleted interval. 
 
We have added the size of the minimal deleted region to the figure as requested. The size of 
each of the individual deletions is recorded in table 1. We felt that annotating them to the 
figure reduced clarity. Due to the  minimal deleted region containing 38 protein coding 
genes (listed in table 2) we also felt that these would be difficult to include in figure 1 in a 
way that could be clearly read. We have not updated the legend to help highlight that this 
information is available within the tables. 
   
9.    Is any of the genes in the interval imprinted? Imprinting would be a fourth 
mechanism that the authors can include in the discussion. Moreover, there are 
defects of imprinted genes known to cause hyperinsulinism (e.g., 11p15 region) and 
neonatal diabetes. 
 
We agree that disruption of imprinted genes is a possible mechanism of disease in 
individuals with large CNVs. We had checked the genes in the minimal deleted region but 
none are known to be imprinted (Baran et al The landscape of genomic imprinting across 
diverse adult human tissues. Genome Res. 2015 Jul;25(7):927-36). We have now added a 
sentence to the discussion to reflect this point. 
 
10.    Discuss whether haploinsufficiency for the genes in the interval are responsible 
for any known syndromes and whether these syndromes have been associated to 
hypoglycemia. 
 
Further information to highlight which of the genes within the deleted region are reported 
to cause disease when disrupted have now been included in table 2. With the exception of 
SLC1A1 none of these genes have been associated with hypoglycaemia. The OMIM record 
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for SLC1A1 list fasting hypoglycaemia as a feature however this information is taken from a 
case report published in 1974 (Teijema et al: Dicarboxylic aminoaciduria: An inborn error of 
glutamate and aspartate transport with metabolic implications, in combination with a 
hyperprolinemia, Metabolism 23:115, 1974) prior to discovery of the SLC1A1 gene (Bailey et 
al Loss-of-function mutations in the glutamate transporter SLC1A1 cause human 
dicarboxylic aminoaciduria. J. Clin. Invest. 121: 446-453, 2011).  
 
11.    Can the authors estimate the frequency of the hypoglycemia among all reported 
cases of 9p deletions? This estimate would help understanding whether mutations on 
the undeleted allele might be implicated. Given the apparently higher frequency of 
hypoglycemia in 9p deletion cases, one would predict that the underlying mechanism 
for hypoglycemia it cannot be due to unmasking of a recessive allele. 
 
We do not believe that it would be accurate to offer a prediction on the frequency of 
hypoglycaemia in the 9p deletion syndrome based on published cases as this does not 
provide an unbiased cross-sectional cohort. We agree with the reviewer that unmasking of a 
recessive allele is unlikely, we hope we have addressed this point adequately in the 
discussion.  
   
12.    Add DECIPHER ID for the case included on fig. 1. 
The ID for the Decipher case has now been included on figure 1.    
Competing Interests: None
Reviewer Report 19 December 2019
https://doi.org/10.21956/wellcomeopenres.16912.r37375
© 2019 Del Roio Liberatore Junior R. This is an open access peer review report distributed under the terms of 
the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Raphael Del Roio Liberatore Junior   
Pediatric Endocrinology‐Pediatric Diabetology and Metabology Section, Department of Pediatrics, 
School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirao Preto, Brazil 
The authors studied 12 patients with 9p deletion syndrome who had hypoglycaemia in the 
neonatal period in an attempt to find a genetic cause to explain hypoglycaemia. 
 
Hypoglycaemia is a very uncommon symptom of 9p deletion syndrome and hyperinsulinism has 
recently been described in patients with 9p deletion syndrome as a cause for hypoglycaemia in 
these patients. Thus, the study proposal is appropriated and justified. 
 
Regarding clinical aspects, the authors report that patients 03 and 12, although presenting 
hypoglycaemia, did not have confirmation of hyperinsulinism. In addition, these 2 patients did not 
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require treatment. 
 
The experimental approach is quite elegant and complete, with the aim of finding a genetic cause 
for hypoglycaemia in 9p deletion syndrome patients. Unfortunately, this cause was not found. 
 
However, here are some considerations:
In the fourth paragraph of the introduction, the authors report that in 55% of cases of 
congenital hyperinsulinism, no genetic causes are found. Thus, I believe that major 
contribution of this research could be that candidate genes present in the lost region of 
chromosome 9 do not explain the occurrence of congenital hyperinsulinism. I believe that 
patients 03 and 12 may be excluded from the sample and the title could may be changed to: 
Refinement of the critical genomic region for congenital hyperinsulinism in chromosome 9p 
deletion syndrome. 
 
1. 
Still regarding patients 03 and 12, it is not clear what was the cause of the episode(s) of 
hypoglycaemia. These patients may have hypopituitarism, especially patient 03, who may 
have changes in the medial line. 
 
2. 
It was not clear in the manuscript if the genes known to be related to congenital 
hyperinsulinism have being studied. 
 
3. 
Interestingly, although 9p deletion syndrome is described as gonadal dysgenesis and sex 
reverse, only patients 1, 4, and 8 had genital alterations. I don't know if the authors paid 
attention to this fact.
4. 
 I would be absolutely satisfied with the answer to these considerations that even reduce the  
importance and elegance of the present study.
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
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Reviewer Expertise: Pediatric Endocrinology
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 24 Jul 2020
Sarah Flanagan, University of Exeter Medical School, Exeter, UK 
The authors studied 12 patients with 9p deletion syndrome who had hypoglycaemia in 
the neonatal period in an attempt to find a genetic cause to explain hypoglycaemia. 
 
Hypoglycaemia is a very uncommon symptom of 9p deletion syndrome and 
hyperinsulinism has recently been described in patients with 9p deletion syndrome as 
a cause for hypoglycaemia in these patients. Thus, the study proposal is appropriated 
and justified. 
 
Regarding clinical aspects, the authors report that patients 03 and 12, although 
presenting hypoglycaemia, did not have confirmation of hyperinsulinism. In addition, 
these 2 patients did not require treatment. 
 
The experimental approach is quite elegant and complete, with the aim of finding a 
genetic cause for hypoglycaemia in 9p deletion syndrome patients. Unfortunately, this 
cause was not found. 
 
1.    In the fourth paragraph of the introduction, the authors report that in 55% of 
cases of congenital hyperinsulinism, no genetic causes are found. Thus, I believe that 
major contribution of this research could be that candidate genes present in the lost 
region of chromosome 9 do not explain the occurrence of congenital hyperinsulinism. 
I believe that patients 03 and 12 may be excluded from the sample and the title could 
may be changed to: Refinement of the critical genomic region for congenital 
hyperinsulinism in chromosome 9p deletion syndrome. 
 
We thank the reviewer for their constructive appraisal of our manuscript. We would like to 
keep patients 03 and 12 within the cohort as we believe that it is important to report that 
there may be variability in the biochemical hypoglycaemic screens in these patients. That 
said, we agree that there is overwhelming evidence that these deletions result in 
hyperinsulinemic hypoglycaemia in the majority of patients and as such we have now 
altered the title as suggested to reflect this point.  
 
2.    Still regarding patients 03 and 12, it is not clear what was the cause of the 
episode(s) of hypoglycaemia. These patients may have hypopituitarism, especially 
patient 03, who may have changes in the medial line. 
 
Thank you for highlighting this point; cortisol deficiency was excluded in all patients 
clinically and biochemically at diagnosis and no patients had evidence of growth failure. 
 The paper has now been updated to reflect this. 
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3.    It was not clear in the manuscript if the genes known to be related to congenital 
hyperinsulinism have being studied. 
 
We apologise that this was unclear. We have now updated the methodology section to 
clarify which patients within our cohort underwent targeted next-generation sequencing. 
 
4.    Interestingly, although 9p deletion syndrome is described as gonadal dysgenesis 
and sex reverse, only patients 1, 4, and 8 had genital alterations. I don't know if the 
authors paid attention to this fact.   
 
We agree it is interesting that of the 7 individuals in our cohort with a 46XY karyotype only 3 
had gonadal dysgenesis. The variable penetrance with this phenotype is included within the 
discussion.   
Competing Interests: None
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